{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:45:15Z","timestamp":1771562715253,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.bmcl.2005.07.058","type":"journal-article","created":{"date-parts":[[2005,9,7]],"date-time":"2005-09-07T15:58:28Z","timestamp":1126108708000},"page":"2337-2340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases"],"prefix":"10.1016","volume":"16","author":[{"given":"Lain-Yen","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"Boxer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne R.","family":"Kesten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huangshu J.","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Wustrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Moreland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd R.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Fahnoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satavisha","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglass C.","family":"Fahnoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert W.","family":"Probert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin L.","family":"Roof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael F.","family":"Rafferty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine R.","family":"Kostlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey D.","family":"Scholten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Hood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald P.","family":"Schielke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ti-Zhi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles P.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Hasemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Ohren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2005.07.058_bib1_1","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1046\/j.1471-4159.1998.71020863.x","volume":"71","author":"Hutson","year":"1998","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bmcl.2005.07.058_bib1_2","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1016\/S0021-9258(18)53663-2","volume":"268","author":"Hall","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmcl.2005.07.058_bib1c","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1074\/jbc.273.9.4982","volume":"273","author":"Davoodi","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmcl.2005.07.058_bib2_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0169-328X(99)00318-6","volume":"75","author":"Kholodilov","year":"2000","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.bmcl.2005.07.058_bib2_2","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1046\/j.1471-4159.2001.00156.x","volume":"76","author":"Lieth","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bmcl.2005.07.058_bib3","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1091\/mbc.11.5.1919","volume":"11","author":"Jouvet","year":"2000","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.bmcl.2005.07.058_bib4_1","unstructured":"Determination of IC50 values for BCAT inhibitors. The reaction mixtures (200\u03bcl) contained 25mM NaPi (pH 7.8), 0.75mM l-leucine, 0.5mM \u03b1-ketoglutarate, 10\u03bcM pyridoxal phosphate, 1mM NAD+, 4mM ADP, 2mM dithiothreitol, 12.5mM EDTA, the indicated compound, saturating level of glutamate dehydrogenase (GDH), and 50\u2013100nM hBCATc. The final concentration of DMSO was kept at 1%. The reactions were carried out in 96-well clear polystyrene plates. The reaction was incubated at 37\u00b0C and the absorbance at 340nm was collected over a period of 20min with readings using a SpectraMax Microplate Spectrophoto-meter\u00ae (Molecular Devices, Palo Alto, CA) equipped with Softmax Pro\u00ae software (Molecular Devices, Palo Alto, CA). IC50s were calculated from 8 to 10 point curves. Human BCATc was expressed in Escherichia coli and purified according to the method described.1c Glutamate dehydrogenase from bovine liver (Sigma) was purified further, as previously described.4b The amount of GDH was determined for each preparation to ensure the saturating level for the assay;"},{"key":"10.1016\/j.bmcl.2005.07.058_bib4b","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0167-4838(96)00100-8","volume":"1297","author":"O\u2019Carra","year":"1996","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bmcl.2005.07.058_bib5","unstructured":"Inhibitors were solubilized in DMSO at a primary concentration of 10mM and then diluted to give a final concentration between 0.3 and 100\u03bcM. The assay is done in a 96-well plate. Total reaction volume of 100\u03bcl consisted of 58\u03bcl reaction mixture with 2\u03bcl of specified inhibitor and 38\u03bcl water. The reaction was started with 2\u03bcl BCAT enzyme. The 96-well reaction plate was incubated for 30min at 37\u00b0C. The reaction was stopped with 100\u03bcl of 2% acetic acid (1% Final) and analyzed for glutamate with LC\/MS\/MS."},{"key":"10.1016\/j.bmcl.2005.07.058_bib6_1","unstructured":"Cultures were prepared, as described in Ref. 6b. Ten- to fourteen-day-old cerebrocortical cultures (48-well plates) were washed once with 500ml of 37\u00b0C HBSS and then plated with 500\u03bcl of 37\u00b0C supplemented MEM (see formula below). A 2\u03bcl volume of test agents (in 100% DMSO) was then spiked in at 260 times final desired concentrations. Plates were stored in a humidified CO2 incubator at 37\u00b0C for 2h by which time 30\u03bcCi\/ml 45Ca in MEM [0.60\u03bcCi\/ml final concentration] was added. Plates were then stored for one additional hour in a humidified CO2 incubator at 37\u00b0C and then spiked with 10\u03bcl of either dH2O or 26mM l-trans-pyrrolidine-2,4-dicarboxylate (LPDC) [500\u03bcM final concentration]. Plates were then store in a humidified CO2 incubator at 37\u00b0C. 45Ca uptake was determined thirty minutes following the addition of LPDC. Cultures were washed trice with 500ml HBSS and then dissolved with lysate buffer. Individual lysates were combined with 10ml scintillation cocktail and counted for emissions using a Tricarb 2900TR Packard Liquid Scintillation Analyzer;"},{"key":"10.1016\/j.bmcl.2005.07.058_bib6b","first-page":"148","volume":"19","author":"Marcoux","year":"1988","journal-title":"Stroke"},{"key":"10.1016\/j.bmcl.2005.07.058_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1006852306789","volume":"174","author":"Schulz","year":"1997","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bmcl.2005.07.058_bib8","unstructured":"The study began with 3 days of dosing with compound 2 at 30mg\/kg, SC, BID (60mg\/kg\/day) and continued daily for 14 days. The mitochondrial inhibitor 3-nitropropionic acid (3-NP, 46mg\/kg, IP) was administered every other day up to day 9 (day 1 defined by the first day of 3-NP dosing). Behavioral testing was done at baseline, during 3-NP administration (day 6), at day 14 (3 days after the end of compound 2 dosing), and again at day 20. Data in Figure 3 represent the maximum effect seen on two of the motor function endpoints. As evaluated by ANOVA, there was an overall statistical difference for each of the behavioral endpoints, and Bonferroni corrected post hoc t-tests were used for specific comparisons. After dosing and behavioral tests, the rats were cardiac-perfused, washed with cold saline, and brains were removed. The right hemispheres were immediately immersed into 4% paraformaldehyde and kept under 4\u00b0C for at least a week. The brain samples were then paraffin embedded and continuous brain sections (40\u03bcm in thickness) were obtained from olfactory bulb to the end of occipital cortex. Every 8th section was processed for cupric silver staining that demonstrates degenerative areas.11 For evaluation of brain damage, sections were examined with a light microscope for detecting positive staining black areas that implied areas of neuronal death. Total number of sections with the positive findings from each group was finally compared with other groups (Newman\u2013Keuls)."},{"key":"10.1016\/j.bmcl.2005.07.058_bib9_1","unstructured":"All the compounds were synthesized by coupling the aryl sulfonyl chloride and aryl carboxylic acid hydrazide in pyridine, as described in compound 2. Compound 2: A solution of 2-trifluorophenyl sulfonyl chloride (1mmol) and 5-chloro-benzofuran-2-carboxy-lic acid hydrazide (1mmol) was stirred for 18h at room temperature in pyridine (10ml). After the pyridine was removed in vacuo, the residue was washed with water and purified by column over SiO2 eluting with 1:2 EtOAc\/hexanes (60% yield). MS: 419.9 (M+1 for C16H10N2O4SF3Cl); mp: 192\u2013193.4\u00b0C. Analysis (C16H10N2O4SF3Cl) calcd. C: 45.89, H: 2.41, N: 6.69, S: 7.66, F: 13.61. Found: C: 46.16, H: 2.41, N: 6.60, S: 7.38, F: 13.30. 1H NMR (DMSO-d6) \u03b4 7.44 (dd, 1H, J=9.04 and 2.20Hz), 7.53 (s, 1H), 7.63 (d, 1H, J=8.79Hz), 7.75\u20137.82 (m, 2H), 7.84 (d, 1H, J=1.95Hz), 7.93 (dd, 1H, J=2.2 and 9.03Hz), 8.13 (dd, 1H, J=2.44 and 6.59Hz), 10.19 (s, 1H), and 11.06 (s, 1H);"},{"key":"10.1016\/j.bmcl.2005.07.058_bib9_2","unstructured":"Hu, L.-Y.; Kesten, S.R.; Lei, H.; Wustrow, D.J.; Ryder, T.R.E.P. EP 1,314,723, 2003."},{"key":"10.1016\/j.bmcl.2005.07.058_bib10a","unstructured":"Tripos Associates, St. Louis, MO;"},{"key":"10.1016\/j.bmcl.2005.07.058_bib10b","unstructured":"Coordinates have been deposited with the RCSB Protein Data Bank with the ID cods 2ABJ."},{"key":"10.1016\/j.bmcl.2005.07.058_bib11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1177\/019262330002800109","volume":"28","author":"Switzer","year":"2000","journal-title":"Toxicol. Pathol."}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X05009406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X05009406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T05:38:48Z","timestamp":1760765928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X05009406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0960894X05009406"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2005.07.058","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The design and synthesis of human branched-chain amino acid aminotransferase inhibitors for treatment of neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2005.07.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}